Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma | Zendy

Zhengyu Wei | Zendy; Cataldo Doria | Zendy; Yuan Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma

Author(s) -

Zhengyu Wei,

Cataldo Doria,

Yuan Liu

Publication year - 2013

Publication title -

clinical medicine insights oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.601

H-Index - 26

ISSN - 1179-5549

DOI - 10.4137/cmo.s7633

Subject(s) - sorafenib , medicine , hepatocellular carcinoma , clinical trial , targeted therapy , liver cancer , oncology , intensive care medicine , cancer

Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treatment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research